Hodgkin's lymphoma Posts - Page 4 of 38 on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

How effective is involved field radiotherapy after autologous hematopoietic stem-cell transplantation in patients with high-risk relapsed/refractory lymphoma?

How effective is involved field radiotherapy after autologous hematopoietic stem-cell transplantation in patients with high-risk relapsed/refractory lymphoma?

Posted by on Apr 4, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors assessed the safety and efficacy of involved-field radiotherapy (IFRT) after autologous hematopoietic stem-cell transplantation (ASCT) in patients with high-risk relapsed/refractory (r/r) lymphoma. The study found that IFRT given soon after ASCT provided durable responses and was well tolerated in these patients. Some...

Read More

Evaluating the effectiveness of BGD therapy in relapsed/refractory Hodgkin lymphoma

Evaluating the effectiveness of BGD therapy in relapsed/refractory Hodgkin lymphoma

Posted by on Mar 28, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of the BGD (bendamustine, gemcitabine, and dexamethasone) regimen in patients with previously treated Hodgkin lymphoma (HL). This study concluded that BGD is well-tolerated and highly effective in these patients.  Some background Hodgkin lymphoma (HL) is a cancer that...

Read More

Long-term outcomes of patients with relapsed or refractory nodular lymphocyte-predominant Hodgkin lymphoma

Long-term outcomes of patients with relapsed or refractory nodular lymphocyte-predominant Hodgkin lymphoma

Posted by on Mar 28, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate the long-term outcomes of patients with relapsed or refractory (r/r) nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). The data showed that first- and second-line therapies are effective over the long-term for these patients. Some background NLPHL is an uncommon type of Hodgkin lymphoma (HL). It...

Read More

Relapsed or refractory Hodgkin lymphoma: how does stopping and restarting nivolumab impact patient outcomes?

Relapsed or refractory Hodgkin lymphoma: how does stopping and restarting nivolumab impact patient outcomes?

Posted by on Mar 28, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate the safety and effectiveness of stopping and restarting nivolumab (Opdivo) in patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).   The authors concluded that nivolumab retreatment is well tolerated and effective in patients who achieved complete response (CR; complete...

Read More

Is PET-guided exclusion of radiotherapy an appropriate treatment regimen for unfavorable early-stage Hodgkin lymphoma?

Is PET-guided exclusion of radiotherapy an appropriate treatment regimen for unfavorable early-stage Hodgkin lymphoma?

Posted by on Mar 21, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors investigated the impact of removing radiotherapy (RT) from treatment regimens in patients with early-stage unfavorable Hodgkin lymphoma (HL). This study concluded that this treatment regimen is just as effective as the standard of care.  Some background Chemotherapy and consolidation RT is the standard of care for...

Read More

Evaluating the effectiveness of brentuximab vedotin and AVD chemotherapy combination in high-risk patients with advanced classical Hodgkin lymphoma

Evaluating the effectiveness of brentuximab vedotin and AVD chemotherapy combination in high-risk patients with advanced classical Hodgkin lymphoma

Posted by on Feb 21, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the long-term safety and effectiveness of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and brentuximab vedotin (Adcedris; A) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combinations in high-risk patients with advanced classical Hodgkin lymphoma (cHL). The data showed that the A+AVD...

Read More

Evaluating the combination of brentuximab vedotin with ipilimumab and nivolumab in relapsed/refractory Hodgkin lymphoma.

Evaluating the combination of brentuximab vedotin with ipilimumab and nivolumab in relapsed/refractory Hodgkin lymphoma.

Posted by on Feb 7, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of combination regimens of brentuximab vedotin (BV; Adcetris), ipilimumab (Yervoy), and nivolumab (Opdivo) in patients with relapsed/refractory Hodgkin lymphoma (HL). The data showed that the treatment combinations had promising effectiveness and manageable side effects. Some background...

Read More

Comparing BEAM to MITO/MEL regimens before autologous hematopoietic stem cell transplantation in patients with Hodgkin lymphoma.

Comparing BEAM to MITO/MEL regimens before autologous hematopoietic stem cell transplantation in patients with Hodgkin lymphoma.

Posted by on Feb 2, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors compared the BEAM (BCNU, etoposide, cytarabine, and melphalan) and MITO/MEL (mitoxantrone, melphalan) regimens before autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma (HL). The study found that both regimens were similarly effective with fewer lung side effects with MITO/MEL.  Some...

Read More

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Posted by on Jan 17, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of GDP (gemcitabine, dexamethasone, and cisplatin) and ICE (ifosfamide, carboplatin, and etoposide) regimens as salvage therapy in patients with relapsed/refractory aggressive lymphoma. The data showed that both the GDP and ICE regimens are suitable options for relapsed/refractory...

Read More

Relapsed or refectory Hodgkin’s lymphoma: how does therapy after autologous transplant impact patient outcomes?

Relapsed or refectory Hodgkin’s lymphoma: how does therapy after autologous transplant impact patient outcomes?

Posted by on Jan 17, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study reviewed treatment options to improve the outcomes of patients with Hodgkin’s lymphoma (HL) treated with an autologous stem cell transplant (ASCT).  Some background HL is a type of blood cancer. Patients with HL who do not respond to chemotherapy are given a transplant of their own healthy stem cells. The...

Read More

The effectiveness of chemotherapy and radiotherapy in nodular lymphocyte predominant Hodgkin lymphoma depending on disease stage

The effectiveness of chemotherapy and radiotherapy in nodular lymphocyte predominant Hodgkin lymphoma depending on disease stage

Posted by on Dec 31, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the effectiveness of chemotherapy and radiotherapy (CRT) in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL).  This study concluded that combined CRT may be more effective in patients with early-stage NLPHL, particularly in older patients.  Some background...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor